645 related articles for article (PubMed ID: 28527899)
1. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA
J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899
[TBL] [Abstract][Full Text] [Related]
2. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
John T; Akamatsu H; Delmonte A; Su WC; Lee JS; Chang GC; Huang X; Jenkins S; Wu YL
Lung Cancer; 2018 Dec; 126():133-138. PubMed ID: 30527177
[TBL] [Abstract][Full Text] [Related]
3. EGFR T790M mutation testing within the osimertinib AURA Phase I study.
Dearden S; Brown H; Jenkins S; Thress KS; Cantarini M; Cole R; Ranson M; Jänne PA
Lung Cancer; 2017 Jul; 109():9-13. PubMed ID: 28577957
[TBL] [Abstract][Full Text] [Related]
4. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
6. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Yang JC; Ahn MJ; Kim DW; Ramalingam SS; Sequist LV; Su WC; Kim SW; Kim JH; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin CC; Mann H; Cantarini M; Ghiorghiu S; Jänne PA
J Clin Oncol; 2017 Apr; 35(12):1288-1296. PubMed ID: 28221867
[TBL] [Abstract][Full Text] [Related]
9. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
Li C; Jia R; Liu H; Zhang B; Wang C
Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
[TBL] [Abstract][Full Text] [Related]
10. [Osimertinib (Tagrisso
Giroux Leprieur E; Cortot AB; Cadranel J; Wislez M
Bull Cancer; 2016 Oct; 103(10):815-821. PubMed ID: 27641462
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
13. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
14. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.
Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C
Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383
[TBL] [Abstract][Full Text] [Related]
15. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
17. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
[TBL] [Abstract][Full Text] [Related]
18. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
[TBL] [Abstract][Full Text] [Related]
19. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
